Michael M. Abecassis

Hepatology · 2009–2019

A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Michael M. Abecassis trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jordi Bruix1 , 2

Papers from Michael M. Abecassis's perspective

Ordered by how strongly the researchers Michael M. Abecassis trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  2. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
  4. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
  5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  6. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)
  7. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
  8. Management of hepatocellular carcinoma: An update (Hepatology)
  9. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
  10. Non-Alcoholic Fatty Liver Disease and Hepatocellular Cancer: A Systematic Review (Clinical Gastroenterology and Hepatology)

Their papers